AEROVATE THERAPEUTICS INC. - COMMON STOCK

Aerovate Therapeutics Announces Second Quarter 2022 Financial Results

15 أغسطس 2022 07:50:00 بحسب Nasdaq GlobeNewswire

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

02 يونيو 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

16 مايو 2022 17:15:00 بحسب Nasdaq GlobeNewswire

Aerovate Therapeutics Announces First Quarter 2022 Financial Results

16 مايو 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Full-Year 2021 Financial Results

30 مارس 2022 16:45:00 بحسب Nasdaq GlobeNewswire

Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference

02 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

15 ديسمبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

17 سبتمبر 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

16 أغسطس 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors

19 يوليو 2021 08:00:00 بحسب Nasdaq GlobeNewswire